Kazia Therapeutics Files Prospectus Supplement
Ticker: KZIA · Form: 424B3 · Filed: Apr 15, 2026
Sentiment: neutral
Topics: prospectus-supplement, securities-offering, filing
TL;DR
Kazia Therapeutics filed a 424B3 prospectus supplement on 4/15/26. Potential stock offering incoming.
AI Summary
Kazia Therapeutics Ltd. filed a prospectus supplement (424B3) on April 15, 2026, related to its securities. The filing originates from Sydney, Australia, with the company's mailing and business addresses both located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Why It Matters
This filing indicates potential upcoming securities offerings or updates to existing ones by Kazia Therapeutics, which could impact investors and the company's capital structure.
Risk Assessment
Risk Level: medium — Prospectus supplements often precede stock offerings, which can dilute existing shareholders or signal a need for capital, carrying inherent risks.
Key Numbers
- 424B3 — Form Type (Indicates a prospectus supplement filing)
- 0001075880 — CIK Number (Unique identifier for Kazia Therapeutics Ltd.)
Key Players & Entities
- Kazia Therapeutics Ltd. (company) — Filer of the prospectus supplement
- 0001075880 (company) — CIK number for Kazia Therapeutics Ltd.
- 2026-04-15 (date) — Filing date of the 424B3 form
- THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000 (location) — Mailing and business address for Kazia Therapeutics Ltd.
FAQ
What is the purpose of a 424B3 filing?
A 424B3 filing is a prospectus supplement used to provide additional information or update details about securities previously registered with the SEC.
When was this prospectus supplement filed by Kazia Therapeutics Ltd.?
The prospectus supplement was filed on April 15, 2026.
Where is Kazia Therapeutics Ltd. based?
Kazia Therapeutics Ltd. is based in Sydney, Australia, with its business and mailing addresses at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
What is the CIK number for Kazia Therapeutics Ltd.?
The CIK number for Kazia Therapeutics Ltd. is 0001075880.
What type of securities might this filing relate to?
While not explicitly stated in this excerpt, a 424B3 filing typically relates to common stock, preferred stock, debt securities, or other types of securities previously registered.
Filing Details
This Form 424B3 (Form 424B3) was filed with the SEC on April 15, 2026 regarding KAZIA THERAPEUTICS LTD (KZIA).